China** Daily Amman was smashed at the opening of the market, and then it once pulled nearly 13% in the intraday. What happened to WuXi AppTec today? 
The answer lies in an announcement after market hours on February 5. Just now, WuXi AppTec announced that on February 5, 2024, the company will repurchase the shares of A-share companies for the first time through centralized bidding transactions, and repurchase the most ** RMB 5172 yuan shares, minimum repurchase ** RMB 4650 yuan shares, the average repurchase price is 49321 yuan shares, with a total amount of RMB 1 billion (excluding transaction costs). It is worth noting that WuXi AppTec said that it will repurchase a total of 2027 A shares this time50,000 shares will be cancelled in accordance with relevant regulations and the share repurchase plan. 
In other words, after the company successfully pry the board this morning, it repurchased all the way, pulling the stock price up to nearly 3%. However, as the selling pressure continued to increase in the afternoon, as of **, the stock price **396%。WuXi AppTec's H-shares were once nearly 10% in early trading, and as of **, they are still **4%. 
The buyback plan was just released the previous trading dayOn the morning of February 2, in order to maintain the stock price, WuXi AppTec announced the repurchase report. The company intends to repurchase A shares through the Shanghai ** Exchange system in a centralized bidding transaction, with a total amount of 1 billion yuan to be repurchased, and the repurchase ** will not exceed 1009 yuan shares (inclusive), that is, not higher than 150% of the average trading price of the company in the 30 trading days before the board of directors passed the resolution to repurchase shares. The repurchased shares are intended to be used for cancellation and reduction of registered capital. At that time, WuXi AppTec planned to complete a repurchase of 1 billion yuan within three months. 
After the repurchase plan was announced, WuXi AppTec's A-share share price fell slightly, and then crashed in the afternoon. H-shares fell by more than 20% again. A "bloody case" triggered by a proposalThe stock price has been **nearly 40%.On January 26, it was rumored in the industry that the United States intends to introduce the "Biosecurity Act", which is reported to be mainly used to ensure that foreign biotechnology companies cannot obtain funds from American taxpayers. If passed, it would restrict federally funded medical institutions from using foreign rival biotech products. Among the companies mentioned is WuXi AppTec. WuXi AppTec's A shares dived and fell in the afternoon of the same day, and H shares once fell by more than 30%. In the following 6 trading days, WuXi AppTec's A-shares repeatedly hit the fall limit in intraday trading. So far, WuXi AppTec's A-share price has fallen from around 75 yuan on January 26 to above 45 yuan shares, a cumulative decline of nearly 40%. 
On January 31, the U.S. Senate meeting on the legislative proposal, however, the legislative proposal is still in "introduced" status and has not yet been approved by the Senate. According to the entire legislative approval process, it needs to be deliberated and passed by the Senate and the House of Representatives before it can finally become law, and submitted to the United States**. 
In addition, according to foreign media sources, a U.S. Senate aide and three other sources said on February 2 that the above proposal was postponed in the Senate this week, and the proposal will not be approved by the committee for at least a few weeks. On February 4, WuXi Biologics announced that the draft bill is still in its early stages and is still subject to further review and changes by the U.S. legislature, and has not yet been promulgated and taken effect. The Company has neither a human genomics business nor does it collect human genome data across its various businesses. The Company would like to emphasize that its business operations remain sound and continue to advance in line with its annual and medium-term strategies. The management team is confident in the Company's prospects and does not expect any material adverse changes in the Group's business operations and financial condition. WuXi AppTec also issued a clarification announcement, saying that as a global company with operating bases in Asia, Europe and North America, WuXi AppTec provides a variety of integrated R&D and manufacturing services to empower the global pharmaceutical and medical industry. The Company does not have a human genomics business, and the Company's existing businesses do not collect human genomics data. Moreover, the company is not affiliated with any ** or its military organization. The Company firmly believes that WuXi AppTec has not, is and will not pose a risk to any country in the past, is and will not be a risk to any country, and therefore should not be pre-defined as a "biotechnology company of concern" in the draft. Editor: Xiaomo Review: Muyu